Ehlers-Danlos Syndrome
Opinion Piece: Insurance Abuse
Editor’s Note: The views, thoughts, and opinions expressed in this article belong solely to the author and do not necessarily reflect the position of Patient
Reimagining HIV Treatment: When Monthly Clinic Visits Outperform Daily Pills
Phase 3 VALOR Trial Shows Brepocitinib Improves Outcomes in Dermatomyositis
Can We Fix This Broken Heart? – Part 5
LISTEN TO OUR PODCAST
THE LATEST FROM PATIENT WORTHY
non-small cell lung cancer
Eftilagimod Alfa Setback: Immutep Halts Landmark Lung Cancer Trial Following Futility Analysis
Immutep Limited has announced the discontinuation of TACTI-004, a pivotal Phase III clinical trial investigating eftilagimod alfa (efti) as a first-line treatment for advanced non-small
non-small cell lung cancer
Dizal’s Zegfrovy Delivers Phase 3 Breakthrough in EGFR Exon 20–Mutant NSCLC
As reported on FiercePharma, China-based biotech Dizal Pharmaceutical has reported a pivotal phase 3 success for its oral EGFR inhibitor Zegfrovy (sunvozertinib), marking a potential
Renal cancer
The Luck of the Irish: A Parable of Inheritance, Illness, and Hope
Editor’s Note: The following article was originally written by Kelly Curtin-Hallinan, and shared with us by our friends at Elephants & Tea. This past St.
RSV
FDA Approves RSV Vaccine for Younger Adults: What You Need to Know
Arexvy Now Available for Adults Aged 18–49 with Certain Health Conditions The U.S. Food and Drug Administration has granted approval to expand GSK’s Arexvy respiratory
Rare Disease
FDA Expands GSK’s Arexvy Approval to Younger Adults at Elevated RSV Risk
As reported on PharmaBiz, the US Food and Drug Administration has broadened the approved use of GSK’s respiratory syncytial virus (RSV) vaccine, Arexvy, to include
Niemann-Pick Type C Disease
An Excerpt from “A Ribbon for Your Hair”
Editor’s Note: The following in from author Stephen Policoff, whose book A Ribbon for Your Hair is out today! Introduction When Stephen Policoff’s adopted daughter
Glioma
Telix Pharmaceuticals Advances Brain Cancer Imaging with European Regulatory Submission
A New Solution to Address Critical Gaps in Glioma Diagnosis and Management Telix Pharmaceuticals, a biopharmaceutical company specializing in therapeutic and diagnostic radiopharmaceuticals, has taken
Wet macular degeneration
VIS-101 Demonstrates Favorable Safety and Early Efficacy in Wet AMD
As reported on Healio, a novel biologic targeting two key angiogenic pathways has shown encouraging early results for the treatment of wet age-related macular degeneration
Charcot-Marie-Tooth disease
Jenny Decker’s Journey: An Update
Editor’s Note: This story is a continuation of Jenny Decker’s global sailing voyage. To see the original article, please click here. Many of our Patient
gastric cancer
Imfinzi Achieves European Milestone: First Immunotherapy to Improve Survival in Early Gastric Cancer
AstraZeneca has received European Commission approval for Imfinzi (durvalumab) in combination with FLOT chemotherapy, a landmark achievement representing the first immunotherapy-based regimen to demonstrate survival
Rare Disease
New Pain Medicine Seeking FDA Approval
People with rare and chronic disease often suffer from long term pain. New ways to alleviate this pain are needed. According to a press release
Rare Disease
A Small Taste of Freedom in an Unfree World
“Do not go gentle into that good night. Rage, rage against the dying of the light.” –Dylan Thomas One may have thought, after six months
Obesity
Oral GLP-1 Candidate Aleniglipron Shows Robust Weight Loss and Favorable Tolerability in Phase 2 Program
In a recent press release, Structure Therapeutics has reported encouraging topline results from its Phase 2 ACCESS clinical program evaluating aleniglipron, an investigational once-daily oral
Leigh syndrome
New Hope for Leigh Syndrome
As reported on Inside Precision Medicine, scientists in Germany have made an exciting discovery that could help children with a very rare and serious illness
Lung Cancer
Regulatory Fast-Track Transforms Lung Cancer Treatment Timeline; Gene Therapy Withdrawal Signals Market Challenges
The biotechnology sector witnessed a striking demonstration of expedited drug development this week, with Boehringer Ingelheim receiving FDA approval for an innovative lung cancer therapy
Rheumatoid Arthritis
Elevara Advances Oral CDK4/6 Inhibitor into Mid-stage Rheumatoid Arthritis Trial
As reported by Pharma Times, Elevara Medicines has initiated a phase 2b clinical study evaluating ELV001, an investigational oral CDK4/6 inhibitor, in people with rheumatoid
Triple-negative breast cancer
Dark Sweet Cherries Against Breast Cancer
Pictured above: Giuliana Noratto, Ph.D., (left) and Lauren Stranahan, Ph.D., led research showing that compounds in dark sweet cherries may help slow the growth and
FEATURED
UPCOMING EVENTS
SIGN UP FOR OUR NEWSLETTER
Today we recognize Gould Syndrome Awareness Day — raising awareness for a rare genetic condition that affects many parts of the body. Every share helps bring visibility, understanding, and hope! #gouldsyndrome #gouldsyndromeawarenessday #raredisease #PatientWorthy
Parkinson’s affects millions of people worldwide, including those living with the disease and the caregivers who support them every day. Today, we raise awareness, honor resilience, recognize caregivers, and stand with the entire Parkinson’s community. Together, we can foster understanding, support research, and work toward a future filled with hope and progress.
Let’s keep the conversation moving. 💙
#WorldParkinsonsDay #ParkinsonsAwareness #CaregiversMatter #StrongerTogether #PatientWorthy
Sometimes the most meaningful support comes from hearing, “You’re not alone.” Reply below to share insights, encouragement, or reminders that helped you along the way! #ReplyAll #PatientWorthy #PatientAdvocacy #ShareYourStory
